Patents Examined by Jennifer A Benavides
-
Patent number: 11958903Abstract: The present application provides anti-LAG-3 constructs comprising a single-domain antibody (sdAb) that specifically recognizes LAG-3. Also provided are methods of making and using these constructs.Type: GrantFiled: March 29, 2019Date of Patent: April 16, 2024Assignee: Nanjing Legend Biotech Co., Ltd.Inventors: Wang Zhang, Shuai Yang, Shu Wu, Chuan-Chu Chou
-
Patent number: 11946045Abstract: The present invention relates to variant polypeptides, methods of preparing the variant polypeptides, processes for characterizing the variant polypeptides, compositions and cells comprising the variant polypeptides, and methods of using the variant polypeptides. The invention further relates to complexes comprising the variant polypeptides, methods of producing the complexes, processes for characterizing the complexes, cells comprising the complexes, and methods of using the complexes.Type: GrantFiled: December 30, 2022Date of Patent: April 2, 2024Assignee: Arbor Biotechnologies, Inc.Inventors: Shaorong Chong, Wei-Cheng Lu, Brendan Jay Hilbert, Quinton Norman Wessells, Lauren E. Alfonse, Anthony James Garrity
-
Patent number: 11939382Abstract: The disclosure relates to binding proteins, including antibodies, that bind to Programmed Death-1 (“PD-1”) and T cell immunoreceptor with Ig and ITIM domains (“TIGIT”). The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.Type: GrantFiled: April 29, 2022Date of Patent: March 26, 2024Assignee: MedImmune, LLCInventors: Yariv Mazor, Yue Wang, Gordon Moody, Deepali Malhotra, Michael Overstreet, Eleanor Clancy-Thompson, Karin Lee, Stacy Pryts, Scott Hammond
-
Patent number: 11932702Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.Type: GrantFiled: December 17, 2021Date of Patent: March 19, 2024Assignees: Ablynx N.V., SanofiInventors: Daniel Janssen, Carlo Boutton, Evelyne Dombrecht, Bram Laukens, Paolo Meoni, Lily Pao, Jan Pype, Peter Schotte, Benedikte Serruys, Ana Paula Vintem, Diane Van Hoorick
-
Patent number: 11926672Abstract: The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.Type: GrantFiled: December 18, 2020Date of Patent: March 12, 2024Assignee: Amgen Inc.Inventors: Xin Yu, Jackson Egen, Fernando Garces, Shunsuke Takenaka, AeRyon Kim, Deepali Sawant
-
Patent number: 11926661Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human artemin. Methods for using anti-artemin antibodies and antigen-binding fragments are also provided.Type: GrantFiled: April 19, 2022Date of Patent: March 12, 2024Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Susan D. Croll, Lynn MacDonald, Andrew J. Murphy
-
Patent number: 11912777Abstract: The present invention relates to a novel antibody and antibody fragment that specifically binds to TNFR2 and to a composition comprising said antibody or antibody fragment. In addition, the present invention relates to a nucleic acid encoding the antibody or an antibody fragment thereof and a host cell comprising the same, and to a related use thereof. Besides, the present invention relates to the use of the antibody and antibody fragment for treatment and diagnosis.Type: GrantFiled: December 9, 2022Date of Patent: February 27, 2024Assignee: Nanjing Leads Biolabs Co., Ltd.Inventors: Xiaoqiang Kang, Shoupeng Lai, Xiao Huang, Huan Lin, Yujia Dang
-
Patent number: 11879015Abstract: The present disclosure provides antibodies that bind to OX40 and antigen binding fragments thereof, and use of the antibodies and the antigen binding fragments in the treatment of diseases for example cancers. The antibodies or the antigen binding fragments include a heavy chain variable region including one or more CDRs having an amino acid sequence selected from amino acid sequences as set forth in SEQ ID NOs: 1-12.Type: GrantFiled: April 29, 2022Date of Patent: January 23, 2024Assignee: BIODURO (BEIJING) CO., LTD.Inventors: Xiang Li, Guoqian Sun, Chenguang Cai, Shiying Fu, Ting Yang, Shuang Zhao, Ying Li, Xinyue Dai, Qi Sun, Fengzhi Zhang, Youyou Lin, Yu Chen, Zhengfei Xue, Hui Pang, Ying Bai, Shin-chen Hou
-
Patent number: 11872289Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.Type: GrantFiled: August 1, 2022Date of Patent: January 16, 2024Assignee: DAIICHI SANKYO CO., LTD.Inventors: Johanna Gellert, Anke Flechner, Doreen Weigelt, Antje Danielczyk, Akiko Nagase
-
Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
Patent number: 11865082Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L1.Type: GrantFiled: September 1, 2021Date of Patent: January 9, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Laura Codarri Deak, Douglas Hanahan, Christian Klein, Valeria Nicolini, Pablo Umana, Stephan Wullschleger -
Patent number: 11851485Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.Type: GrantFiled: November 16, 2022Date of Patent: December 26, 2023Assignee: AULOS BIOSCIENCE, INC.Inventors: Inbar Amit, Itay Levin, Guy Nimrod, Sharon Fischman, Reut Barak Fuchs, Marek Strajbl, Timothy Wyant, Michael Zhenin, Olga Bluvshtein Yermolaev, Yehezkel Sasson, Noam Grossman, Natalia Levitin, Yanay Ofran
-
Patent number: 11839660Abstract: Aspects of the disclosure relate to antibodies that bind to transferrin receptor (e.g., transferrin receptor 1) and complexes comprising the antibody covalently linked to a molecular payload. Methods of using the antibodies are also provided.Type: GrantFiled: March 10, 2023Date of Patent: December 12, 2023Assignee: Dyne Therapeutics, Inc.Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden, Cody A. Desjardins, Brendan Quinn, John Najim
-
Patent number: 11834493Abstract: Provided herein are antibodies that are useful for treating SARS-CoV-2 infections in a subject. Also provided herein are compositions comprising one or more antibodies, methods of treatment comprising administering one or more antibodies, and kits comprising one or more antibodies.Type: GrantFiled: January 4, 2022Date of Patent: December 5, 2023Assignee: IMMUNOME, INC.Inventors: Matthew K. Robinson, Pavel Nikitin, Michael John Morin, Jillian Dimuzio, Ray Howanski, John P. Dowling
-
Patent number: 11827718Abstract: Provided herein are antibodies, or antigen-binding portions thereof, which specifically bind to pathologic forms of calcineurin. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and methods for use of these antibodies.Type: GrantFiled: May 19, 2021Date of Patent: November 28, 2023Assignee: University of Kentucky Research FoundationInventors: Susan D. Kraner, Rodney P Guttmann, Christopher M. Norris, Jenna Leigh Gollihue
-
Patent number: 11820820Abstract: An antibody capable of blocking CD47-SIRPa interaction and an application thereof.Type: GrantFiled: June 10, 2019Date of Patent: November 21, 2023Assignee: CHENGDU CONMED BIOSCIENCES CO., LTD.Inventors: Bo Chen, Gang Xu, Xuhong Chen, Feng Li, Boyan Zhang, Sijia Huang
-
Patent number: 11802155Abstract: The present disclosure provides binding agents, such as antibodies, that specifically bind ILT2, ILT4, or both ILT2 and ILT4, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.Type: GrantFiled: April 29, 2021Date of Patent: October 31, 2023Assignee: NGM Biopharmaceuticals, Inc.Inventors: Dana Yen Mei Duey, Allen James Ebens, Jr., Daniel David Kaplan, Chia-Ying Kao Lam, Kalyani Mondal, Geoffrey William Stone, Yan Wang
-
Patent number: 11795227Abstract: The present disclosure provides an immunomodulation and anti-tumor-related nanobody that specifically binds to a human leukocyte antigen-G, a programmed cell death ligand 1, and CD3 ?. The present disclosure also provides the nucleic acid sequence of the immunomodulation and anti-tumor-related nanobody, and use of the immunomodulation and anti-tumor-related nanobody for treating cancer and immune-related disorders.Type: GrantFiled: March 21, 2022Date of Patent: October 24, 2023Assignee: SHINE-ON BIOMEDICAL CO., LTD.Inventors: Der-Yang Cho, Shao-Chih Chiu, Shi-Wei Huang, Chih-Ming Pan, Mei-Chih Chen, Yu-Chuan Lin, Yeh Chen
-
Patent number: 11795228Abstract: The present disclosure relates to antibodies that bind to human CD94, as well as methods, uses, polynucleotides, vectors, host cells, and pharmaceutical compositions related thereto. In some embodiments, the antibodies are human or humanized antibodies that bind to human CD94 and do not block binding between CD94 and HLA-E. In some embodiments, the antibodies cross-react with cynomolgus CD94. In some embodiments, the antibodies do not promote internalization of surface-expressed CD94 to the extent of existing antibodies. In some embodiments, the antibodies promote ADCC targeting cells that express human CD94, e.g., on the cell surface.Type: GrantFiled: September 29, 2021Date of Patent: October 24, 2023Assignee: Dren Bio, Inc.Inventors: Nenad Tomasevic, Ruo Shi Shi
-
Patent number: 11787861Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD200R1 receptor protein (hu-CD200R1) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD200R1. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD200 binding to CD200R1.Type: GrantFiled: May 28, 2021Date of Patent: October 17, 2023Assignee: 23andMe, Inc.Inventors: Yu Chen, Jilean Beth Fenaux, Germaine Fuh-Kelly, Yao-Ming Huang, Wei-Jen Chung, Erik Edward Karrer, Cecilia Lay, Steven J. Pitts, Louise Scharf
-
Patent number: 11760802Abstract: The present disclosure provides binding agents, such as antibodies, that specifically bind ILT3, including human ILT3, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.Type: GrantFiled: December 17, 2020Date of Patent: September 19, 2023Assignee: NGM Biopharmaceuticals, Inc.Inventors: Suzanne Christine Crawley, Jer-Yuan Hsu, Daniel David Kaplan, Betty Chan Li, Vicky Yi-Bing Lin, Seth Malmersjö, Kevin James Paavola, Julie Michelle Roda, Yan Wang